Liensinine, isoliensinine and neferine demonstrate antifibrotic activity across pulmonary, cardiac, endometrial and diabetic cardiomyopathy models, primarily via suppression of TGF-β/Smad, ERK/MAPK signaling and oxidative stress. This evidence concerns the gene TGFB1 and diabetic cardiomyopathy.